Generic Daurismo Availability
Last updated on May 7, 2025.
Daurismo is a brand name of glasdegib, approved by the FDA in the following formulation(s):
DAURISMO (glasdegib maleate - tablet;oral)
-
Manufacturer: PFIZER
Approval date: November 21, 2018
Strength(s): EQ 25MG BASE [RLD], EQ 100MG BASE [RLD]
Is there a generic version of Daurismo available?
No. There is currently no therapeutically equivalent version of Daurismo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daurismo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Patent 10,414,748
Issued: September 17, 2019
Inventor(s): Seadeek Christopher Scott
Assignee(s): Pfizer Inc.This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Patent expiration dates:
- April 13, 2036✓✓
- April 13, 2036
-
Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Patent 11,168,066
Issued: November 9, 2021
Inventor(s): Seadeek Christopher Scott
Assignee(s): Pfizer Inc.This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Patent expiration dates:
- April 13, 2036✓
- April 13, 2036
-
Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Patent 11,891,372
Issued: February 6, 2024
Inventor(s): Seadeek; Christopher Scott
Assignee(s): Pfizer Inc. (New York, NY)This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Patent expiration dates:
- April 13, 2036✓
- April 13, 2036
-
Benzimidazole derivatives
Patent 8,148,401
Issued: April 3, 2012
Inventor(s): Munchhof Michael J. & Reiter Lawrence A. & La Greca Susan D. & Jones Christopher S. & Li Qifang
Assignee(s): Pfizer Inc.The present invention relates to a compound of the Formula I
Patent expiration dates:
- January 30, 2031✓✓
- January 30, 2031
-
Benzimidazole derivatives
Patent 8,431,597
Issued: April 30, 2013
Inventor(s): Munchhof Michael J. & Reiter Lawrence A. & La Greca Susan D. & Jones Christopher S. & Li Qifang
Assignee(s): Pfizer Inc.The present invention relates to a compound of the Formula I
Patent expiration dates:
- June 29, 2028✓
- June 29, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 21, 2025 - INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
More about Daurismo (glasdegib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: hedgehog pathway inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.